Fernand Labrie
Publications
Page 8 of 8, showing 18 records out of 368 total, starting on record 351, ending on 368
| Publication | Category | Year |
|---|---|---|
| 328. Séguin, C., Bélanger, A., Cusan, L., Pelletier, G., Reeves, J.J., Lefebvre, F.A., Kelly, P.A., Labrie, F. (1981) Relative importance of the adenohypophyseal and gonadal sites of inhibitory action of LHRH agonists. Biol. Reprod., 24: 889-901. | Prostate Cancer | 1981 |
| 329. Séguin, C., Cusan, L., Bélanger, A., Kelly, P.A., Labrie, F., Raynaud, J.P. (1981) Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent tissues in the rat. Mol. Cell. Endocrinol., 21: 37-41. | Prostate Cancer | 1981 |
| 227. Simard, J., Labrie, C., Hubert, J.-F., Labrie, F. (1988) Modulation by sex steroids and [D-Trp6, des-Gly-NH210]LHRH ethylamide of a subunit and LH? mRNA levels in the rat anterior pituitary gland. Mol. Endocrinol., 2: 775-784. | Prostate Cancer | 1988 |
| 267. Simard, J., Luthy, I., Guay, J., Bélanger, A., Labrie, F. (1986) Characteristics of interaction of the antiandrogen Flutamide with the androgen receptor in various target tissues. Mol. Cell. Endocrinol., 44: 261-270. | Prostate Cancer | 1986 |
| 247. Soret, J.Y., Verine, J.L., Daver, A., Labrie, F. (1987) Comparative results of the variations in intraprostatic androgen levels and androgen receptors following pulpectomy with or without an antiandrogen (Flutamide) in the treatment of advanced prostate cancer, in: Murphy, G.P., Khoury, S., Kreiss, R., Chatelain, C. et Denis, L., eds: Prostate Cancer Research, Endocrine Treatment and Histopathology. Progress in Clinical and Biological Research, New York, Alan R. Liss Inc., pp 77. | Prostate Cancer | 1987 |
| 248. Soret, Y., Verine, J.L., Daver, A., Labrie, F. (1987) Levels of intraprostatic androgen receptors and intraprostatic testosterone following orchiectomy with or without addition of an antiandrogen (Flutamide) in the treatment of advanced prostatic cancer. J. Drug Dev., 1: 23-25. | Prostate Cancer | 1987 |
| 268. St-Arnaud, R., Lachance, R., Dupont, A., Labrie, F. (1986) Serum luteinizing hormone (LH) biological activity in castrated patients with cancer of the prostate receiving a pure antiandrogen and in estrogen-treated patients treated with an LH-releasing hormone agonist and antiandrogen. J. Clin. Endocrinol. Metab., 63: 297-302. | Prostate Cancer | 1986 |
| 269. St-Arnaud, R., Lachance, R., Dupont, A., Labrie, F. (1986) Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and Flutamide in patients with cancer of the prostate. Clin. Invest. Med., 9: 215-221. | Prostate Cancer | 1986 |
| 270. St-Arnaud, R., Lachance, R., Kelly, S.J., Bélanger, A., Dupont, A., Labrie, F. (1986) Loss of luteinizing hormone (LH) bioactivity in patients with prostatic cancer treated with an LHRH agonist and a pure antiandrogen. Clin. Endocrinol. (Oxf.), 24: 21-30. | Prostate Cancer | 1986 |
| 228. St-Arnaud, R., Poyet, P., Walker, P., Labrie, F. (1988) Androgens modulate epidermal growth factor receptor levels in the rat ventral prostate. Mol. Cell. Endocrinol., 56: 21-27. | Prostate Cancer | 1988 |
| 198. Têtu, B., Labrie, F., Dupont, A., Monfette, G. (1989) Histopathologic effect of combination therapy on normal prostate and prostatic adenocarcinoma, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, Exerpta Medica ICS 841, pp 63-76. | Prostate Cancer | 1989 |
| 317. Tolis, G., Ackman, D., Stellos, A., Mehta, A., Labrie, F., Fazekas, A.T.A., Comaru-Schally, A.M., Schally, A.V. (1982) Tumor growth inhibition in patients with prostatic caricnoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA, 79: 1658-1662. | Prostate Cancer | 1982 |
| 300. Tremblay, Y., Bélanger, A., Labrie, F., Frenette, G., Dubé, J.Y., Tremblay, R.R. (1984) Characteristics of the inhibitory effect of chronic treatment with an LHRH agonist on testicular steroidogenesis in the dog. Prostate, 5: 631-638. | Prostate Cancer | 1984 |
| 301. Tremblay, Y., Bélanger, A., Lacoste, D., Giasson, M., Labrie, F. (1984) Selective inhibition of spermatogenesis in the presence of normal libido following combined treatment with an LHRH agonist and testosterone in the dog. Contraception, 30: 585-598. | Prostate Cancer | 1984 |
| 80. van der Kwast, T., Têtu, B., Suburu, E.R., Gomez, J., Lemay, M., Labrie, F. (1998) Cycling activity of benign prostatic epithelial cells during long-term androgen blockade: evidence for self-renewal of luminal cells. J. Pathol., 186: 406-409. | Prostate Cancer | 1998 |
| 70. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy. Hum. Pathol., 30: 1503-1507. | Prostate Cancer | 1999 |
| 71. van der Kwast, T.H., Labrie, F., Têtu, B. (1999) Prostatic intraepithelial neoplasia and endocrine manipulation. Eur. Urol., 35: 508-510. | Prostate Cancer | 1999 |
| 72. van der Kwast, T.H., Têtu, B., Candas, B., Gomez, J.-L., Cusan, L., Labrie, F. (1999) Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology, 53: 523-529. | Prostate Cancer | 1999 |